Boston Scientific Corp. Announces Results From Quantitative Coronary Angiographic Analysis Of Incidence Of Longitudinal Stent Deformation In PERSEUS And PLATINUM Randomized Clinical Trials

Boston Scientific Corp. announces results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM randomized clinical trials, comprising more than 2,400 patients across three distinct coronary stent platforms: the Platinum Chromium Element platform (ION Paclitaxel-Eluting Stent System (TAXUS Element) and PROMUS Element Everolimus-Eluting Stent System), the Xience V/PROMUS Everolimus-Eluting Stent System, and the TAXUS Express Paclitaxel-Eluting Stent System. This study represents systematic, independent core lab analysis to assess longitudinal stent deformation across multiple drug-eluting stent platforms and provides the first and only reported clinical data to evaluate longitudinal stent deformation based on prospective QCA measurements from randomized trials. The post hoc analysis included QCA data from 2,403 patients who received a single stent in the PERSEUS and PLATINUM Workhorse trials. Stent length, as prospectively measured by QCA during the trials, was compared to the nominal length of the implanted stent. A ratio of 1.0 indicates equivalent measured and nominal stent lengths while a ratio less than 1.0 suggests possible stent shortening and a ratio greater than 1.0 suggests possible stent lengthening. Distributions of the mean QCA-measured versus nominal stent length ratios were compared in the randomized test and control arms of each trial.